{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:18:03Z","timestamp":1769087883443,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3107,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute dyspnoea is a common chief complaint in the emergency department and is mainly caused by cardiac and pulmonary underlying diagnoses. In patients with acute heart failure (AHF), an early initiation of adequate therapy is important to improve patient outcome. Clinical differentiation of pulmonary and cardiac underlying causes and of concomitant pathologies determines which therapeutic strategy is chosen.<\/jats:p>\n                  <jats:p>Procalcitonin is a marker of bacterial infection, which is markedly increased in AHF patients with concomitant bacterial infection and thus has the potential to guide the early initiation of adequate antibiotic therapy. The IMPACT-EU trial is a multicenter randomized controlled trial designed to test this hypothesis.<\/jats:p>\n                  <jats:p>This mini-review summarizes the current literature on procalcitonin in AHF and explains the design of the IMPACT-EU trial.<\/jats:p>","DOI":"10.1002\/ehf2.12189","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T07:48:51Z","timestamp":1500450531000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Role of Procalcitonin in Acute Heart Failure Patients"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-3709","authenticated-orcid":false,"given":"Martin","family":"M\u00f6ckel","sequence":"first","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Division of Emergency and Acute Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Searle","sequence":"additional","affiliation":[{"name":"Division of Emergency and Acute Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Maisel","sequence":"additional","affiliation":[{"name":"University of California San Diego and VA Medical Center , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"2026012115134044300_ehf212189-bib-0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MEJ.0b013e328351e609","article-title":"Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM)","volume":"20","author":"Mockel","year":"2013","journal-title":"Eur J Emerg Med"},{"key":"2026012115134044300_ehf212189-bib-0002","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/eurjhf\/hfr177","article-title":"Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial","volume":"14","author":"Maisel","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012115134044300_ehf212189-bib-0003","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"key":"2026012115134044300_ehf212189-bib-0004","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.92.6.1479","article-title":"Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure","volume":"92","author":"Ferrari","year":"1995","journal-title":"Circulation"},{"key":"2026012115134044300_ehf212189-bib-0005","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"2026012115134044300_ehf212189-bib-0006","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ejheart.2008.02.008","article-title":"Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure","volume":"10","author":"Miettinen","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026012115134044300_ehf212189-bib-0007","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"key":"2026012115134044300_ehf212189-bib-0008","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0002-9149(97)00159-8","article-title":"Elevated soluble CD14 receptors and altered cytokines in chronic heart failure","volume":"79","author":"Anker","year":"1997","journal-title":"Am J Cardiol"},{"key":"2026012115134044300_ehf212189-bib-0009","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","article-title":"Endotoxin and immune activation in chronic heart failure: a prospective cohort study","volume":"353","author":"Niebauer","year":"1999","journal-title":"Lancet (London, England)"},{"key":"2026012115134044300_ehf212189-bib-0010","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijcard.2014.08.106","article-title":"Determinants of procalcitonin concentration in acute heart failure","volume":"177","author":"Mollar","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012115134044300_ehf212189-bib-0011","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/cc13181","article-title":"Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"2026012115134044300_ehf212189-bib-0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2016.10.038","article-title":"Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction","volume":"226","author":"Boulogne","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012115134044300_ehf212189-bib-0013","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ajem.2013.12.045","article-title":"Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial","volume":"32","author":"Travaglino","year":"2014","journal-title":"Am J Emerg Med"},{"key":"2026012115134044300_ehf212189-bib-0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2014.12.009","article-title":"Procalcitonin and long-term prognosis after an admission for acute heart failure","volume":"26","author":"Villanueva","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2026012115134044300_ehf212189-bib-0015","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/bmm.15.29","article-title":"Should procalcitonin be measured routinely in acute decompensated heart failure?","volume":"9","author":"Loncar","year":"2015","journal-title":"Biomark Med"},{"key":"2026012115134044300_ehf212189-bib-0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2015.11.141","article-title":"Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients","volume":"204","author":"Demissei","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012115134044300_ehf212189-bib-0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1378\/chest.06-1500","article-title":"Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy","volume":"131","author":"Stolz","year":"2007","journal-title":"Chest"},{"key":"2026012115134044300_ehf212189-bib-0018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(04)15591-8","article-title":"Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial","volume":"363","author":"Christ-Crain","year":"2004","journal-title":"Lancet (London, England)"},{"key":"2026012115134044300_ehf212189-bib-0019","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2009.1297","article-title":"Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial","volume":"302","author":"Schuetz","year":"2009","journal-title":"JAMA"},{"key":"2026012115134044300_ehf212189-bib-0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10096-009-0851-0","article-title":"Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey","volume":"29","author":"Schuetz","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis: official publication of the European Society of Clinical Microbiology"},{"key":"2026012115134044300_ehf212189-bib-0021","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijcard.2014.06.022","article-title":"Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial","volume":"175","author":"Schuetz","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012115134044300_ehf212189-bib-0022","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026012115134044300_ehf212189-bib-0023","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/3\/203\/66256894\/eschf_4_3_203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/3\/203\/66256894\/eschf_4_3_203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:18:47Z","timestamp":1769026727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/4\/3\/203\/8413097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7,18]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12189","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,7,18]]},"assertion":[{"value":"2017-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}